Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Methotrexate - Amplio Pharma

Next Previous
Drug Profile

Methotrexate - Amplio Pharma

Alternative Names: AMP 101 - Amplio Pharma; Methotrexate Forte - Amplio Pharma; NovoBioJect

Latest Information Update: 17 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Amplio Pharma
  • Class Abortifacients; Amines; Aniline compounds; Anti-inflammatories; Antiasthmatics; Antifibrotics; Antineoplastics; Antipsoriatics; Antirheumatics; Benzamides; Dicarboxylic amino acids; Disease-modifying antirheumatics; Eye disorder therapies; Heart failure therapies; Methylamines; Pentanoic acids; Pteridines; Small molecules
  • Mechanism of Action Immunosuppressants; Tetrahydrofolate dehydrogenase inhibitors; Thymidylate synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Rheumatoid arthritis
  • Clinical Phase Unknown Autoimmune disorders

Most Recent Events

  • 03 Sep 2025 European Medical Agency (EMA) approves regulatory application for methotrexate in Rheumatoid arthritis
  • 03 Sep 2025 Amplio Pharma plans a phase Ib trial for Rheumatoid arthritis
  • 19 Aug 2025 Phase-I clinical trials in Rheumatoid arthritis (Combination therapy) in Netherlands (SC) (CTIS2025-522531-34-00)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top